

Special Issue on
Molecular Reprogramming of Cancer and Cancer Stem Cells

CALL FOR PAPERS

Cancer Stem Cells (CSCs) retain the ability to renew themselves, leading to the heterogeneity of tumors, which are similar to stem cells. It also seems that newly arising cancer cells express self-renewing properties, which are also normally expressed in stem cells. Evidence shows that various cancer-related signaling pathways are also involved in CSCs development. The reprogramming of cancer cells is a promising way to study cancer and CSCs therapy. The relationship between oncogenes or tumor suppressors and the cellular microenvironment is also needed to be studied to elucidate the underlying mechanisms of various stages of cancer progression. Thus, CSCs represent a major concern for current cancer treatment and intervention strategies. To deal with CSCs, cancer cell reprogramming might be one of the prominent approaches to improve cancer treatments by converting them into an immature or benign state. *In vivo* reprogramming strategies can also be used in human pathological situations including various cancers, by which cancer progression and prognosis can be impaired. Moreover, signaling pathways including Notch, Sonic hedgehog (Shh), hippo, Wnt, kinase, and GPCR signaling pathways, associated with oncogenesis, metastasis, epithelial-mesenchymal transition (EMT), or mesenchymal-epithelial transition (MET) might also be targeted in terms of cancer therapy.

This special issue will focus on molecular reprogramming of cancer and CSCs. Of that, research or review articles should be focused on the reprogramming of cancer and CSC cells, or malignant cancer cells to normal or benign tumor cells in relation to new treatment options or other biological and medical applications. This special issue aims not only to summarize the roles of CSCs in the genesis, development, drug resistance, metastasis, and recurrence of various cancers but also to propose potential novel treatment and intervention approaches in the hope of inspiring readers and researchers throughout the world.

Potential topics include but are not limited to the following:

- ▶ *In vitro* and *in vivo* reprogramming of cancer or CSC cells to normal or benign tumor cells
- ▶ Signaling pathways regulating oncogenesis in CSCs
- ▶ Regulation of stemness, invasion, and metastasis in CSCs
- ▶ Epithelial-mesenchymal transition (EMT) or mesenchymal-epithelial transition (MET) mechanism in CSCs
- ▶ Studying the role of oncogenes or tumor suppressor genes in cancer and CSCs using bioinformatics approaches
- ▶ Drug resistance mechanism in cancers and CSCs
- ▶ Recurrence treatment of cancers and CSCs
- ▶ Personalized medicine for cancers and CSCs

Authors can submit their manuscripts through the Manuscript Tracking System at <https://mts.hindawi.com/submit/journals/jo/mrscsc/>.

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor

Subbroto Kumar Saha, Konkuk University, Seoul, Republic of Korea
subbroto@konkuk.ac.kr

Guest Editors

Joydeep Das, Shoolini University, Solan, India
joydeepdas@shooliniuniversity.com

Minchan Gil, Konkuk University, Seoul, Republic of Korea
minchangil@konkuk.ac.kr

Submission Deadline

Friday, 19 July 2019

Publication Date

December 2019